Kyntra Bio Inc

KYNB

Healthcare Biotechnology

Kyntra Bio Inc’s revenue for fiscal 2025 (year ended December 2025) was $6.4 million, down 78.3% from fiscal 2024.

Revenue
n/m
EPS
n/m
Free cash flow
n/m

Quarter to June 2026, against a year earlier

3.44 0.15 −4.18%
Market cap
$14.5M
P/E
0.1×
Fwd P/E FY26e
n/m
Dividend yield
—
F-score
5/9
ROIC
0.00%
Net debt / EBITDA
2.0×
Payout ratio
—

Revenue to profit Twelve months to 30 June 2026

Of every $100 of revenue, $3967.77 was left as profit. Gross margin has fallen three quarters running, from 167.1% to 6.3%. What is an income statement?

Revenue to profit, in billions of dollars and as a share of revenue
Revenue0.0100.0%
Cost of revenue0.0−93.7%
Gross profit0.06.3%
Research & development0.0−495.2%
Selling, general & admin0.0−599.4%
Other operating costs0.0−1.5%
Operating income−0.1−1089.8%
Other income, net0.0420.2%
Income tax0.02.0%
Other items+0.24635.4%
Net income0.23967.8%
Revenue, operating income and net income, four quartersRevenueOperating incomeNet incomeNet margin (right axis)
Revenue, operating income and net income, four quarters
Q3 FY25Q4 FY25Q1 FY26Q2 FY26
Revenue$0.0B$0.0B$0.0B$0.0B
Operating income$0.0B$0.0B$0.0B−$0.1B
Net income$0.2B$0.2B$0.2B$0.2B
Net margin (right axis)2598.6%2848.6%2199.4%3967.8%
Older periods Sep '25 Dec '25 Mar '26 Jun '26
Revenue

+8 more TTM periods

8.30 6.44 7.44 4.62
Cost of Revenue
(5.57) 0.56 4.41 4.33
Gross Profit
13.87 5.88 3.03 0.29
R&D Expenses
23.12 23.52 21.91 22.86
SG&A Expenses
28.81 27.71 25.47 27.67
Operating Income
(39.52) (45.89) (44.79) (50.31)
Non-operating Income/Expense
(12.83) (12.40) (11.87) 19.40
Non-operating Interest Expenses
8.57 8.76 8.93 9.29
EBT
(52.35) (58.29) (56.66) (30.91)
Income Tax Provision
— (0.09) — (0.09)
Income after Tax
(52.26) (58.20) (56.57) (30.91)
Net Income Common
215.65 183.45 163.62 183.19
EPS (Basic)
53.48 45.47 40.46 45.30
EPS (Diluted)
53.38 45.37 40.46 45.30
Shares (Basic, Weighted)
4.03 4.04 4.04 4.05
Shares (Diluted, Weighted)
4.03 4.04 4.04 4.05
Gross Margin
167.09% 91.37% 40.72% 6.28%
EBIT Margin
(476.17%) (712.66%) (602.14%) (1,089.78%)
EBT margin
(630.77%) (905.19%) (761.69%) (669.57%)
Net Profit Margin
2,598.55% 2,848.63% 2,199.42% 3,967.77%
Free Cash Flow Margin
(203.46%) (74.72%) (287.40%) (824.19%)
EBITDA
(38.42) (45.22) (44.62) (50.45)
EBIT
(39.52) (45.89) (44.79) (50.31)
EPS (Diluted, from Cont. Ops)
(12.99) (14.40) (13.99) (7.65)
EPS (Diluted, Consolidated)
53.45 45.38 40.47 45.31
EPS (Diluted, from Disc. Ops)
0.00 0.00 0.00 —
EPS (Basic, Consolidated)
53.45 45.38 40.47 45.31
EPS (Basic, from Discontinued Ops)
66.37 59.77 54.45 —
Shares (Diluted, Average)
4.03 4.04 4.04 4.05
EPS (Basic, from Continuous Ops)
(12.99) (14.40) (13.99) (7.65)
Income from Continuous Operations
(52.26) (58.20) (56.57) (30.91)
Income from Discontinued Operations
267.91 241.66 220.19 —
Consolidated Net Income/Loss
215.65 183.45 163.62 183.19
EBITDA Margin
(463.00%) (702.16%) (599.80%) (1,092.79%)
Operating Cash Flow Margin
(203.78%) (74.13%) (287.40%) (824.19%)

Fold the line items

In millions of $ except per-share values · columns are period end dates · fundamentals updated 25 Oct 2026